Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
05/11/2025
Thai Ministry of Commerce data: Core consumer price index in October increased by 0.61% year-on-year.
Latest
2 m ago
Sichuan Gold established a mining company in Xinjiang.
2 m ago
Kem One New Materials: The company's PEKK products have been applied in various fields such as additive manufacturing.
3 m ago
Bright Ocean Pharmaceutical has obtained the exclusive distribution rights of the albumin product Ambomei in mainland China.
3 m ago
Danish pharmaceutical giant Novo Nordisk has lowered its performance expectations for the fourth time this year, citing lower-than-expected sales of its star drugs, Wegovy and Ozempic. The company said on Wednesday that, based on fixed exchange rates, sales for the year are expected to increase by at most 11% and operating profit by at most 7%, lower than the previous expectations of 14% and 10%, respectively. While Novo Nordisk had initially led the weight loss drug market with Ozempic and Wegovy, the company's fate began to shift last year when an experimental injectable drug failed to deliver on promised weight loss effects in clinical trials. Novo Nordisk is now pinning hopes on an oral version of Wegovy to revive growth. Its stock price has dropped by about half this year.
4 m ago
The US government shutdown impacts the US stock IPO market: SEC reviews are stalled, end-of-year listing pushes are blocked.
See all latest